Why Esperion Therapeutics Plummeted by 11% Today
Esperion Therapeutics (NASDAQ: ESPR) had a day to forget on Monday as its stock lost more than 11% on news that a fresh stack of shares would be coming to the market.
Esperion announced Monday morning that it has entered into a private agreement with two holders of its convertible senior subordinated notes to convert those securities into common stock. In total, those investors hold notes with an aggregate principal value of $15 million.
Image source: Getty Images.
Source Fool.com
